New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

1

Key data on U.S. J&J, Moderna COVID-19 boosters weeks away, Fauci says

Data needed to determine the advisability of booster shots of the Moderna Inc. and Johnson & Johnson Covid-19 vaccines is just weeks away, President Joe Biden’s chief medical adviser, Dr. Anthony Fauci, said on Sept. 19.

2

Mirati drug combination shrinks tumors in 39% of colon cancer patients in study

A combination of Mirati Therapeutics Inc.’s genetic mutation-targeting adagrasib and Eli Lilly and Co.’s older cancer drug Erbitux shrank tumors in 39 percent of patients with advanced colorectal cancer treated in a small trial, the company said on Sept. 19.

3

FDA advisers recommend COVID boosters for 65 and older after rejecting broad approval

Advisers to the U.S. Food and Drug Administration voted on Sept. 17 to recommend Covid-19 vaccine booster shots for Americans 65 and older and those at high risk of severe illness, after overwhelmingly rejecting a call for broader approval.

4

EQRx and CStone Tout Data from Trial of Firsts at ESMO 2021

Non-small cell lung cancer (NSCLC) is one of the most devestating diagnoses and highest unmet needs in the oncology space. EQRx, which intends to solve pricing and access challenges for patients, unveiled new data at the European Society for Medical Oncology (ESMO) Congress 2021 showing that it might just have the answer to NSCLC too.

5

Research Roundup: Link Between Herpes Simplex Virus and Neurogenerative Diseases Gets More Support

Researchers at the University of Illinois at Chicago published what they are calling a “first of its kind study” that found a possible direct link between neurodegenerative diseases and the herpesvirus.

6

Vifor Licenses Rare Kidney Disease Drug in Comeback for Travere

Vifor Pharma and Travere Therapeutics inked a collaboration and licensing partnership to commercialize sparsentan in Europe, Australia and New Zealand. The drug is being developed to treat FSGS and IgAN, which are rare progressive kidney diseases that are leading causes of end-stage kidney disease.

7

DOJ Pushes Back on Purdue Settlement that Would Shield Sackler Family

Although the U.S. Bankruptcy Court approved the OxyContin maker’s reorganization plan that freed the Sacklers from greater financial accountability and shielded them from additional lawsuits, the Department of Justice moved to block the Purdue Pharma bankruptcy deal.